齐拉西酮治疗育龄期女性精神分裂症的临床研究

目的探讨齐拉西酮对育龄期女性精神分裂症的疗效及安全性。方法 56例育龄期女性精神分裂症患者随机分为研究组和对照组,各28例,研究组用齐拉西酮治疗,对照组用喹硫平治疗,共观察8周。采用阳性和阴性综合征量表（PANSS）及治疗中需处理的不良反应症状量表（TESS）评定疗效和不良反应。结果研究组和对照组的显效率分别为78.57%和75.00%,两组显效率比较无显著性差异（χ2=0.100,P﹥0.05）;治疗8周后研究组和对照组PANSS总分及各因子分与治疗前比较均显著下降（P〈0.01）,两组治疗第2、4、6、8周末的PANSS总分及各个因子分比较均无显著性差异（P＞0.05）;对照组头昏和头晕、体质量增加、月经改变发生率高于研究组（P〈0.05）。结论齐拉西酮不影响患者的体质量和月经,是治疗育龄期女性精神分裂症安全有效的药物。

A clinical research of Ziprasidone in treatment of schizophrenic women in child-bearing period

Objective To explore the efficacy and safety of ziprasidone in the treatment of schizophrenic women in child- bearing period. Methods 56 female patients with schizophrenia in child - bearing period were randomly divided into study group （28 cases） treated with ziprasidone and control group （28 cases） treated with quetiapine for 8 weeks. All patients were assessed with Positive and Negative Syndrome Scale （PANSS） and Treatment Emergent Symptom Scale （TESS） at the end of week 2, week 4, week 6 and week 8 to evaluate the efficacy and side effects. Results There was no significant difference in response rate between study group and control group （78.57% vs. 75.00%, X2 =0. 100, P 〉0.05）. Compared with baseline, total score and all factor scores of PANSS decreased significantly in both group at the end of the treatment （P 〈0.01 ）. There were no significant differences in total score and factor scores of PANSS between the two groups at the end of week 2, week 4, week 6 and week 8 （P 〉 0.05）. The incidence rate of dizziness, weight gain and menoxenia in control group were significantly higher than those in study group （P 〈 0.05）. Conclusion Ziprasidone dose not affect female patients＇ body weight and menstruation. It is safe and effective for treating female patients with schizophrenia in child-bearing period.